Inventiva S.A. (IVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - The company is focused on developing lanifibranor, a pan-PPAR agonist, currently in Phase III study for MASH [1] - Lanifibranor is designed to mitigate the liabilities associated with previous PPARs, such as Actos and Avandia, by creating a more moderate gamma binder [1] - The design approach emphasizes the interconnectedness of PPAR networks, aiming for a balanced effect across all PPARs [1]